drugset / Trial / NCT04517539

Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors

NCT04517539

Phase 2 Unknown 65 enrolled Shanghai Cancer Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Peginterferon alfa-2b is safe, effective in the treatment of patients with metastatic thymic epithelial tumors.

Timeline

Start
2020-12-01
Primary completion
2022-12-01
Completion
2022-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-b2 Protein / enzyme biologic 90 ug Subcutaneous
Subject rhGM-CSF Protein / enzyme biologic 125 ug/m2 Subcutaneous
Subject rhGM-CSF Protein / enzyme biologic 125 mg/m2 Subcutaneous